U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. HONA

Go back to U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
(NASDAQ: RVMD) Delayed: 210.02 -0.85 (0.4%)
Previous Close $210.87    52 Week High $ 
Open $209.01    52 Week Low $ 
Day High $211.75    P/E N/A 
Day Low $207.48    EPS $ 
Volume 885,062